BioSpace News Archive

Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Oxurion NV announced that it has enrolled more than two-thirds of the planned total enrollment in its KALAHARI Phase 2, Part B clinical trial.

Yield10 Bioscience, Inc., an agricultural bioscience company, reported financial results for the fourth quarter and full year ended December 31, 2022.

Decibel Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

Prothena Corporation plc announced broad participation at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders being held March 28 – April 1, 2023 in Gothenburg, Sweden, highlighting Prothena’s leadership in advancing next generation treatments for Alzheimer’s and Parkinson’s disease.

Kezar Life Sciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Sigilon Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022 as well as certain other business highlights.

NANOBIOTIX announces that it will provide an operational update and report its financial results for full-year ending December 31, 2022, on Tuesday, March 28, 2023, after the close of the US market.

OnkosXcel Therapeutics, LLC announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock following its conversion into a corporation.